Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors (Q37603360)

21 August 2017

1 reference

title

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors (English)

1 reference

21 August 2017

1 reference

Sergey S Seregin

1

1 reference

21 August 2017

Andrea Amalfitano

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1521-1531

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Systems biology of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Gene therapy for immune disorders: good news tempered by bad news

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

AAV vector integration sites in mouse hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Characterization of a permissive epitope insertion site in adenovirus hexon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Detailed analysis of the CD8+ T-cell response following adenovirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus-based genetic vaccines for biodefense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Development of a preventive vaccine for Ebola virus infection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

New insights on adenovirus as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus protein IX: a new look at an old protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

The adenovirus capsid: major progress in minor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Genetic targeting strategies for adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Use of chimeric adenoviral vectors to assess capsid neutralization determinants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Improvements in gene therapy: averting the immune response to adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Structure-based identification of a major neutralizing site in an adenovirus hexon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Hexon gene switch strategy for the generation of chimeric recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Extensive cross-reactivity of adenovirus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Early adenoviral gene expression mediates immunosuppression by transduced dendritic cell (DC): implications for immunotherapy using genetically modified DC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Induction and inhibition of innate inflammatory responses by adenovirus early region proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Adenovirus DNA polymerase is recognized by human CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Helper-dependent adenoviral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Replication-defective vector based on a chimpanzee adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903307388

10.1517/14712590903307388

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference